Related Experiment Video
Updated: May 30, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study
Aikaterini Patsatsi1, Aikaterini Kyriakou, Dimitrios Sotiriadis
12nd Dermatology Department, Aristotle University School of Medicine, Thessaloniki, Greece.
The Journal of Dermatological Treatment
|July 30, 2011
Summary
Ustekinumab significantly improved nail psoriasis symptoms, with complete remission achieved in many patients by week 40. This study highlights ustekinumab
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Ustekinumab is approved for psoriasis treatment, but its effectiveness for nail psoriasis requires further investigation.
- Nail involvement is a common and often debilitating manifestation of plaque psoriasis.
Purpose of the Study:
- To evaluate the therapeutic efficacy of ustekinumab in patients with moderate-to-severe plaque psoriasis and nail involvement.
Main Methods:
- An open-label, uncontrolled study enrolled 27 patients with moderate-to-severe plaque psoriasis and nail disease.
- Patients received subcutaneous ustekinumab 45 mg at baseline, week 4, and every 12 weeks thereafter.
- Nail Psoriasis Severity Index (NAPSI) and Psoriasis Area and Severity Index (PASI) were assessed at baseline and weeks 16, 28, and 40.
Main Results:
- NAPSI scores significantly decreased from a median of 73.0 at baseline to 0.0 by week 40.
- Median PASI scores also showed significant improvement, decreasing from 23.9 at baseline to 0.0 by week 40.
- By week 40, 100% median improvement in NAPSI and 100% median improvement in PASI were observed.
Conclusions:
- Preliminary data suggest ustekinumab is highly effective for treating nail psoriasis.
- Ustekinumab demonstrates significant potential as a therapeutic option for patients with psoriatic nail disease.
